Abstract:Lay Summary What does this mean for patients? Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a type of coronavirus that causes coronavirus disease 2019 (COVID-19). Spread of SARS-CoV-2 led to the COVID-19 pandemic and a global threat to public health. Different variants of SARS-CoV-2 have developed as the virus changes over time. Omicron is one such variant. Patients with systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis, systemic lupus erythematosus and Sjogren's syndrome, are often treated with drugs called immunosuppressants. Immunosuppressants make the immune system less active, meaning that it is harder to defend against diseases such as COVID-19. As a result, SARD patients are at higher risk of developing severe COVID-19. We performed a study to describe the characteristics and immune responses of SARD patients with COVID-19 Omicron infection in China. We found that SARD patients had fewer antibodies against Omicron than healthy people. We also found that lupus patients who used biologic drugs had a lower antibody level than those using glucocorticoids (steroids) and/or hydroxychloroquine. Importantly, SARD patients who had at least two doses of SARS-CoV-2 vaccine had higher levels of antibodies than unvaccinated patients. These findings suggest that patients with SARDs have a lower antibody response after Omicron infection than healthy people, meaning that their immune systems are less able to defend against future re-infection. Our data therefore support the importance of COVID-19 booster vaccination among patients with SARDs. Objectives The surge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron infections has affected most Chinese residents at the end of 2022, including a number of patients with systemic autoimmune rheumatic diseases (SARDs). Methods To investigate the antibody level of the Omicron variant in SARD patients after SARS-CoV-2 Omicron infection, we tested BA.5.2 and BF.7 Omicron variant IgG antibody levels using ELISA on blood samples collected from 102 SARD patients and 19 healthy controls (HCs). The type of SARD, demographics, concurrent treatment, doses of SARS-CoV-2 vaccines and outcomes were also recorded. Results A total of 102 SARD patients (mean age: 40.3 years; 89.2% female), including 60 SLE, 32 RA and 10 other SARDs, were identified. Of these, 87 (85.3%) were infected with SARS-CoV-2. We found that the BA.5.2 and BF.7 antibody levels of infected SARD patients were lower than those of HCs (P < 0.05). Sixty-five (63.7%) patients had at least one dose of a SARS-CoV-2 vaccine. SARD patients with at least two doses of SARS-CoV-2 vaccine had a higher level of BA.5.2 and BF.7 antibodies than the unvaccinated group (P < 0.05). There was no evidence for a significant inhibitory effect of glucocorticoids (GCs) on the BA.5.2 and BF.7 Omicron variant antibody levels in SARD patients. SLE patients using biologic DMARDs had a lower BA.5.2 Omicron variant antibody level than patients using GCs and/or HCQ. Conclusion These data suggest that patients with SARDs had a lower antibody response than HCs after Omicron infection.

Escalating SARS-CoV-2 specific humoral immune response in rheumatoid arthritis patients and healthy controls

Comparison of SARS-COV-2 humoral response between rheumatoid arthritis, psoriatic arthritis and spondyloarthritis patients and controls in two unvaccinated cohorts

Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients

Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series

Humoral immunity to an endemic coronavirus is associated with postacute sequelae of COVID-19 in individuals with rheumatic diseases

SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic

Tracking the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity within 2 years after COVID-19 infection

SARS-CoV-2 mRNA vaccine-induced immune responses in rheumatoid arthritis

Antibody Responses Following the Surge of SARS-CoV-2 Omicron Infection among Patients with Systemic Autoimmune Rheumatic Diseases.

Effect of Immunosuppression on the Immune Response to SARS-CoV-2 Infection and Vaccination

404. Impact of cross-coronavirus humoral immunity in post-acute sequelae of COVID-19 in systemic autoimmune rheumatic diseases patients

SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

A stronger antibody response in increased disease severity of SARS-CoV-2

Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis

Determination of the factors associated with antigen-specific CD4+ T-cell responses to BNT162b2 in patients with rheumatoid arthritis

Differential decline of SARS-CoV-2-specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID-19

Study of the humoral immune response against SARS-CoV-2 post-infectious and post-vaccination

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study

The Immunogenicity and Safety of Three Types of SARS-CoV-2 Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Longitudinal Cohort Study

Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection